Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113256 · ClinicalTrials.gov registry record · Phase 2
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00113256 is a Phase 2 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT00113256, a Phase 2 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated.
Interventions
- DRUG Rubitecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113256
The ClinicalTrials.gov registry entry for NCT00113256 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rubitecan is the first listed.
NCT00113256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113256 about?
NCT00113256 is a clinical study titled "Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer". Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated...
What is the current status of trial NCT00113256?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00113256?
The interventions under investigation include: Rubitecan (DRUG).
Who is sponsoring clinical trial NCT00113256?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.